MDACC Study No:2008-0275 ( NCT No: NCT00814073)
Title:A 24-week with possible extension, prospective, multicentre, randomized, double blind, placebo-controlled, 2-parallel group with a randomization 1:1, Phase III study to compare efficacy and safety of masitinib at 6 mg/kg/day to placebo in treatment of patients with Smouldering Systemic, Indolent Systemic or Cutaneous Mastocytosis with handicap
Principal Investigator:Srdan Verstovsek
Treatment Agent:Masitinib
Study Status:Closed
Study Description:The goal of this clinical research study is to compare the benefits of
treatment with masitinib to no treatment in patients with mastocytosis with
Hide details for General InformationGeneral Information

Disease Group:Hematologic Disorder
Phase of Study:Phase III
Treatment Agents:Masitinib
Treatment Location:Both at MDACC & outside MDACC at one or more Collaborating Sites or Institutions
Estimated Length of Stay in Houston:N/A
Supported By:AB Science
Return Visit:Eligible patients will be treated with masitinib or matching placebo for 24
weeks with possible extension. Patients will be seen every 4 Weeks during the
protocol period, and then every 12 weeks during the possible extension period.
Home Care:Self Medicated

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Srdan Verstovsek
For Clinical Trial Enrollment:713-745-3429
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults